Renalytix plc Stock: price and insider trades · United States
1 insider bought €82k of shares over the last 90 days, the latest by Harwood Capital LLP*, filed 01 Oct 2026.
Renalytix plc: what insiders have been doing
This page follows insider dealings at Renalytix plc as filed with SEC (Form 4), a company from the Health Care sector. In the past year (22 October 2025 to 22 October 2026), 2 filings came from 2 insiders.
Only purchases show up on the open market, 2 purchases in all worth €83k, filed by 2 insiders. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The buyers include 1 finance chief and 1 senior executive. The largest single trade was a purchase of €82k by Harwood Capital LLP*, published on 1 October 2026, equal to 0.17% of the market capitalisation.
The latest purchase dates back some time: it was published 38 days ago, on 1 October 2026.
Compared with its exchange (277 companies, median 8 filings), a count of 2 filings is below the norm. The full history, which starts in 2021, counts 2 purchases against 4 sales.
In the same sector, recent insider purchases at UCB also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- +34.9%Entry US$2.70 · Close 21 Oct 2026 US$3.65
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended June 2025 · cache
- 1,166,667 shares@ £0.060.17% mcap1.3% of flowLondon Stock Exchange, AIMISIN GB00BYWL4Y04RNS:9805076Canonical exit: 28 Dec 2026 (T+90)
- 500 shares@ £2.85100.0% of flowOTC New YorkRNS:ca6a735a-8987-4ba4-ba5f-8c1714f2bf7aCanonical exit: 12 May 2026 (T+90)
- 13,366,750 shares@ US$0.11639.4% of flowOrdinary SharesSEC:0000950170-24-121609:0
- 83,696 shares@ £8.0012.9% of flowLondon Stock Exchange, AIMRNS:5385335-0
- 500,000 shares@ £9.0087.1% of flowOff marketRNS:5385335-1
- 9,360,374 shares@ US$0.2560.6% of flowOrdinary SharesSEC:0000950172-24-000236:0
- 6,100 shares@ £11.25100.0% of flowLondon Stock ExchangeISIN GB00BYWL4Y04FCA-NSM:4023723
- ▼Executives193,000 GBP19FCA-NSM
- 2,554,398 shares@ US$6.68100.0% of flowOutside a trading venueISIN GB00BYWL4Y04FCA-NSM:3946430
9 of 9 declarations
About Renalytix plc
Renalytix plc is a company focused on developing diagnostic solutions for kidney diseases. It leverages advanced technologies to enhance the management of patients with chronic kidney conditions.
